On 3/30/2017, Shares of Timken Steel Corporation (NYSE:TMST) closed at $18.15 in last trading day. After noting the initial trading entry at $17.97, it reached to a day’s high of $18.52 and moved to a day’s low of $17.82. The recent daily volume was 548 thousand as contrast to it’s an average volume of 629.27 thousand.
The last close of the Timken Steel Corporation stock reflects that it traded -5.05% from its 50-day moving average of $19.11. The stock traded above +22.06% to its 200-day MA of $14.87. Furthermore, it moved lower -21.09% from its 52-week high of $23.00 and +121.78% up from $8.18, which is 52-week low of the stock.
TimkenSteel Corporation’s (TMST) moved with shift of 0.83% in the past week. Over the last three months, the shares of the company have changed 13.15% and performed 78.47% over the last six months. The stock currently has Monthly Volatility of 4.86% and Weekly Volatility of 4.51%.
TimkenSteel Corporation manufactures and sells alloy steel, and carbon and micro-alloy steel products worldwide. It offers carbon, micro-alloy, and alloy steel ingots, bars, and tubes; and precision components, as well as thermal treatment and machining services. The company’s products are used in oil country drill pipes; bits and collars; gears; hubs; axles; crankshafts and connecting rods; bearing races and rolling elements; bushings; fuel injectors; wind energy shafts; anti-friction bearings; and other demanding applications It sells its products and services to the oil and gas, oil country tubular goods, automotive, industrial equipment, mining, construction, rail, aerospace and defense, heavy truck, agriculture, and power generation sectors. TimkenSteel Corporation is headquartered in Canton, Ohio.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) finalized the last transaction at value of $3.34, with a daily change of -2.62% or -0.09 points. The company maintained volume of 523.75 thousand shares. In past trading day, the stock hit the maximum price of $3.49 and touched to minimum value of $3.27. It has a market cap of $ 168.42M.
As of last trade close, the stock is trading downside -49.62% from its one year high of $6.63 and moved +297.52% upward from $0.84, which is one year low of the stock.
The stock traded above +16.09% from its 50-day moving average of $2.88. Furthermore, the stock moved up +82.90% to its 200-day MA of $ 1.83.
During the last month, Infinity Pharmaceuticals, Inc.’s (INFI) has changed 11.33% and performed 111.39% over the last 6 months. The mean rating score for this stock is at 3.00. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 9.90% in recent month and observed Weekly Volatility of 6.14%.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.